Placental protein tyrosine nitration and MAPK in type 1 diabetic pre-eclampsia: Impact of antioxidant vitamin supplementation

J Diabetes Complications. 2013 Jul-Aug;27(4):322-7. doi: 10.1016/j.jdiacomp.2013.02.001. Epub 2013 Apr 2.

Abstract

Aim: To examine the role of placental protein tyrosine nitration and p38-Mitogen-Activated Protein Kinase α (p38-MAPKα), Extra Cellular-Signal Regulated Kinase (ERK) and c-Jun NH2-Terminal Kinase (JNK) activity, in the pathogenesis of type 1 diabetic pre-eclampsia, and the putative modulation of these indices by maternal vitamin C and E supplementation.

Methods: Placental samples were obtained from a sub-cohort of the DAPIT trial: a randomised placebo-controlled trial of antioxidant supplementation to reduce pre-eclampsia in type 1 diabetic pregnancy. Placenta from placebo-treated: normotensive (NT) [n=17], gestational hypertension (GH) [n=7] and pre-eclampsia (PE) [n=6] and vitamin-treated: NT (n=20), GH (n=4) and PE (n=3) was analysed. Protein tyrosine nitration was assessed by immunohistochemistry in paraffin-embedded tissue. Catalytic activities of placental p38-MAPKα, ERK and JNK were measured by enzyme-linked immunosorbent assay (ELISA).

Results: Nitrotyrosine immunostaining was present in placebo-treated NT, GH and PE placentae, with no significant difference observed between the groups. There was a non-significant trend towards decreased p38-MAPKα activity in PE vs NT control placentae. ERK and JNK were similar among the three outcome placebo groups and vitamin supplementation did not significantly alter their activity.

Conclusion: Nitrotyrosine immunopositivity in normotensive diabetic placentae indicates some degree of tyrosine nitration in uncomplicated diabetic pregnancy, possibly due to inherent oxidative stress and peroxynitrite production. Our results suggest that p38-MAPKα, ERK and JNK are not directly involved in the pathogenesis of type 1 diabetic pre-eclampsia and are not modulated by vitamin-supplementation.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antioxidants / pharmacology*
  • Antioxidants / therapeutic use
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / metabolism
  • Dietary Supplements
  • Extracellular Signal-Regulated MAP Kinases / metabolism*
  • Female
  • Humans
  • Nitrates / metabolism*
  • Placebos
  • Placenta / metabolism*
  • Pre-Eclampsia / drug therapy
  • Pre-Eclampsia / metabolism*
  • Pregnancy
  • Pregnancy Proteins / metabolism*
  • Pregnancy in Diabetics / drug therapy
  • Pregnancy in Diabetics / metabolism
  • Protein Processing, Post-Translational
  • Tyrosine / metabolism
  • Vitamins / pharmacology*
  • Vitamins / therapeutic use

Substances

  • Antioxidants
  • Nitrates
  • Placebos
  • Pregnancy Proteins
  • Vitamins
  • Tyrosine
  • Extracellular Signal-Regulated MAP Kinases